Israël -
hébreu -
Ministry of Health
מאקרוביד
k.s.kim international (sk- pharma) ltd., israel - nitrofurantoin anhydrous; nitrofurantoin macrocrystals - קפסולות - nitrofurantoin anhydrous 75 mg; nitrofurantoin macrocrystals 25 mg - nitrofurantoin
Israël -
hébreu -
Ministry of Health
פוראור ברייט - ג'ל לצחצוח השיניים למבוגרים וילדים ללא פלואריד
פוראור ליוינג פרודקטס (ישראל) בעמ - צחצוח שיניים
Israël -
hébreu -
Ministry of Health
אוויפלרה
j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir disoproxil as fumarate - טבליות מצופות פילם - tenofovir disoproxil as fumarate 245 mg; rilpivirine as hydrochloride 25 mg; emtricitabine 200 mg - rilpivirine - rilpivirine - eviplera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is indicated for use as a complete regimen for the treatment of hiv-1 infection in antiretroviral treatment-naive adults. this indication is based on week 48 safety and efficacy analyses from 2 randomized, double-blind, active controlled, phase 3 trials in treatment-naive subjects comparing rilpivirine to efavirenz . the following points should be considered when initiating therapy with eviplera: -more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure compared to subjects with hiv-1 rna less than 100,000 copies/ml at the start of therapy. -the observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the nnrti class compared to efavirenz . -more subjects treated with rilpivirine developed lamivudine/emtricitabine associated resistance compared to efavirenz. -eviplera is not recomme
Israël -
hébreu -
Ministry of Health
אוויפלרה
j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir disoproxil as fumarate - טבליות מצופות פילם - tenofovir disoproxil as fumarate 245 mg; rilpivirine as hydrochloride 25 mg; emtricitabine 200 mg - rilpivirine - rilpivirine - eviplera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is indicated for use as a complete regimen for the treatment of hiv-1 infection in antiretroviral treatment-naive adults. this indication is based on week 48 safety and efficacy analyses from 2 randomized, double-blind, active controlled, phase 3 trials in treatment-naive subjects comparing rilpivirine to efavirenz . the following points should be considered when initiating therapy with eviplera: -more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure compared to subjects with hiv-1 rna less than 100,000 copies/ml at the start of therapy. -the observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the nnrti class compared to efavirenz . -more subjects treated with rilpivirine developed lamivudine/emtricitabine associated resistance compared to efavirenz. -eviplera is not recomme
Israël -
hébreu -
Ministry of Health
פרוברה 5 מג
pfizer pfe pharmaceuticals israel ltd - medroxyprogesterone acetate - טבליה - medroxyprogesterone acetate 5 mg - medroxyprogesterone - medroxyprogesterone - in cases requiring progesterone supplement.
Israël -
hébreu -
Ministry of Health
דיקלופטיל % 0.1
bioavenir ltd, israel - diclofenac sodium - תמיסה - diclofenac sodium 0.1 %v/v - diclofenac - diclofenac - post-operative inflammation following cataract extraction. control of ocular pain and discomfort associated with corneal epithelial defects after laser excimer prk or accidental trauma.
Israël -
hébreu -
Ministry of Health
וולטרן אופטה טיפות עיניים
novartis israel ltd - diclofenac sodium - טיפות עיניים - diclofenac sodium 1 mg/ml - diclofenac - diclofenac - post-operative inflammation following cataract extraction. control of ocular pain and discomfort associated with corneal epithelial defects after laser excimer prk or accidental trauma.